ENGN enGene Therapeutics Inc.: institutional ownership and insider trading
55 funds reported holding $67.4M of enGene Therapeutics Inc. in their latest 13F filings; in Q2 2026 funds net bought $66.9M, with 55 new positions and 1 funds selling out; over the last 12 months insiders bought $10.1K and sold $0 on the open market.
Famous investors holding ENGN
- Izzy Englander (Millennium Management): $1.67M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.44M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $1.35M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $285K, 0.0% of the portfolio
Largest institutional holders of ENGN
- BML Capital Management, LLC — $11.5M
- Siren, L.L.C. — $10.8M
- PERCEPTIVE ADVISORS LLC — $8.34M
- AMERIPRISE FINANCIAL INC (AMP) — $4.63M
- Nextech Invest, Ltd. — $4.02M
- ADAR1 Capital Management, LLC — $3.64M
- Vestal Point Capital, LP — $2.88M
- ACORN CAPITAL ADVISORS, LLC — $2.20M
- Peapod Lane Capital LLC — $2.08M
- BALYASNY ASSET MANAGEMENT L.P. — $1.74M
Recent ENGN insider trades
- Sep 22, 2026: Grossman William bought 5,102 shares ($10.1K)
- Oct 30, 2024: Forbion Growth Opportunities Fund I Cooperatief U.A. bought 561,797 shares ($5.00M)
5%+ owners
- Raymond Debbane: 9.3% (Schedule 13G/A, filed Aug 13, 2026)